Inhibikase Therapeutics, Inc. (IKT) — Institutional Holders, Q2 2026 (page 2)
106 institutional investment managers reported a IKT position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $240.8M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 101 to 106. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
IKT 13F holders ranked 101–106 of 106
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 101 | PNC FINANCIAL SERVICES GROUP#101 · 81 sh | 81 | $164.00 | 0.00% | 0.0% |
| 102 | Quarry#102 · 55 sh | 55 | $112.00 | 0.00% | New |
| 103 | SJS Investment Consulting#103 · 32 sh | 32 | $65.00 | — | +255.6% |
| 104 | IFP Advisors#104 · 23 sh | 23 | $47.00 | — | +666.7% |
| 105 | Clearstead Advisors#105 · 6 sh | 6 | $13.00 | 0.00% | New |
| 106 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#106 · 1,501 sh | 1,501 | — | — | -74.5% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.